The Institute for Clinical and Economic Review (ICER) has established a starting point for discussion about the price of Gilead’s COVID-19 treatment, Remdesivir, BioPharma Dive reports.
According to the report, ICER says the drug would be cost-effective as high as $4,460, a higher estimate than some expected.
“The consequential discussion about the tradeoffs and priorities involved with different pricing approaches cannot wait,” ICER President Steven Pearson said in a statement.
To read BioPharma Dive’s report, click here.
Click here to read InsideHealthPolicy’s report on ICER’s assessment. (Paid subscription required)